. Author manuscript; available in PMC: 2017 Dec 1.

Published in final edited form as: Cancer Chemother Pharmacol. 2016 Nov 5;78(6):1245–1252. doi: 10.1007/s00280-016-3183-7

Table 3.

Median percent changes in plasma VEGF during dosing and washout periods (range shown in parenthesis)

	Median % change during drug dosing period		Median % change during drug washout period
	Cycle 1	Cycle 3	Cycle 1	Cycle 3
PD cohort (5 mg BID)	140 (−40 to 3787)	193 (15–1363)	−63 (−95 to 0)	−67 (−82 to −39)
Safety cohort (7 mg BID)	99 (27 to 442)	–	−27 (−52 to −4)	–

Comparison between cycle 1 and cycle 3 could not be completed for the safety cohort due to patients coming off study prior to completing cycle 3

PD pharmacodynamic